DNX Biopharmaceuticals Overview

  • Founded
  • 2014

  • Status
  • Private

  • Employees
  • 9

  • Latest Deal Type
  • Angel

  • (Cancelled)
  • Latest Deal Amount
  • $5M

  • Investors
  • 1

DNX Biopharmaceuticals General Information


Owner and operator of a biopharmaceutical company intended to develop long-acting therapeutic proteins for the treatment of patients with life-long diseases. The company's biopharmaceutical services focus on development of new therapeutic proteins utilizing a half-life extension platform that produces therapeutic proteins and biological drugs to treat auto-inflammatory diseases, enabling medical researchers to facilitate treatment of rheumatoid arthritis and other related diseases, while off-setting the development cost through therapeutic proteins and biological drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 19800 MacArthur Boulevard
  • Suite 300
  • Irvine, CA 92612
  • United States
+1 (949) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DNX Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 01-Jul-2016 $5M Cancelled Startup
1. Accelerator/Incubator 14-May-2016 Completed Startup
To view DNX Biopharmaceuticals’s complete valuation and funding history, request access »

DNX Biopharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Rajiv Datar Ph.D Co-Founder & Chief Executive Officer
Claude Gingras Chief Financial Officer
Jeff Hale Chief Business Officer
John Caputo Co-Founder & Board Member
To view DNX Biopharmaceuticals’s complete executive team members history, request access »

DNX Biopharmaceuticals Board Members (4)

Name Representing Role Since
Howard Levine Ph.D DNX Biopharmaceuticals Co-Founder & Board Member 000 0000
John Caputo DNX Biopharmaceuticals Co-Founder & Board Member 000 0000
Thomas Zindrick JD Self Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

DNX Biopharmaceuticals Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DNX Biopharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EvoNexus Accelerator/Incubator 000 0000 000000 0
To view DNX Biopharmaceuticals’s complete investors history, request access »